Precipio Adds Another HemeScreen™ Customer
June 09, 2020 10:00 ET
|
Precipio, Inc.
NEW HAVEN, Conn., June 09, 2020 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced that Cancer and Hematology Centers of Western Michigan (CHCWM) has adopted...
First Substantial Customer: Tennessee Oncology Internalizes Precipio’s HemeScreen™
September 30, 2019 11:10 ET
|
Precipio, Inc.
NEW HAVEN, Conn., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced that Tennessee Oncology has selected Precipio’s HemeScreen RUO assay as...
Global Expansion Efforts Begin Yielding Results
July 22, 2019 10:00 ET
|
Precipio, Inc.
NEW HAVEN, Conn., July 22, 2019 (GLOBE NEWSWIRE) -- Specialty Diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today that in conjunction with its global expansion efforts, it has begun...
Precipio’s HemeScreen™ Adopted by Methodist Health
April 03, 2019 07:38 ET
|
Precipio, Inc.
NEW HAVEN, Conn., April 03, 2019 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today that Methodist Hospital, located in Memphis, TN, has selected...
Precipio Files Patent for HemeScreen™, its Novel Molecular Assay
January 08, 2019 07:45 ET
|
Precipio, Inc.
NEW HAVEN, Conn., Jan. 08, 2019 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), today announced the filing of a patent for its proprietary HemeScreen panel....
Precipio Launches HemeScreen™, a Disruptive, Proprietary Molecular Test for Hematologic Cancers
October 03, 2018 07:47 ET
|
Precipio, Inc.
Impacts a $100M annual US laboratory market by reducing testing costs through a simple, screening assay NEW HAVEN, Conn., Oct. 03, 2018 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company...